Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
49actual
Sites
28
Countries
Belgium, Brazil, Denmark +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-19 | actual | When the study began enrolling |
| Primary completion | 2025-03-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-25 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Intervention
- Drug: Itepekimab SAR440340 — also filed as REGN3500
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in itepekimab pharmacodynamic normalized enrichment score (NES) derived from former smokers in endobronchial biopsies in current smokers with COPD
measured Baseline to Week 12
Change from baseline in itepekimab pharmacodynamic NES derived from former smokers in bronchial brushings in current smokers with COPD
measured Baseline to Week 12
Change from baseline in itepekimab pharmacodynamic NES derived from former smokers in nasal brushings in current smokers with COPD
measured Baseline to Week 12
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed